QTTB’s AKB-097 Acquisition Spurs Rare Kidney Disease Pipeline at Akebia: Multi-Year Collaboration and Phase 2 Trials Ahead

Asset Purchase of AKB-097 Marks Major Pipeline Expansion

Akebia Therapeutics, a leading player in kidney disease treatments, has significantly expanded its rare kidney disease pipeline through a major asset acquisition from Q32 Bio Inc. (NASDAQ:QTTB). The highlight: Akebia now holds exclusive rights to AKB-097, a next-generation complement inhibitor originally developed as ADX-097 at Q32 Bio, signaling an intensified commitment to innovation in the treatment of complex kidney disorders.

Pipeline Strategy: Focused on Complement and sGC Modulation

The newly announced pipeline features two core investigational drugs. The first is AKB-097—a humanized, tissue-targeted monoclonal antibody fusion protein complement inhibitor. This therapy aims to offer more selective disease targeting with reduced risk compared to existing systemic inhibitors, and will be tested across multiple rare kidney disease subtypes in a Phase 2 basket trial planned to start in 2026.

Additionally, praliciguat, an oral soluble guanylate cyclase (sGC) stimulator, will be studied in a Phase 2 clinical trial targeting focal segmental glomerulosclerosis (FSGS), with up to 60 patients enrolled in the U.S. Notably, both assets have demonstrated positive tolerability and pharmacokinetic profiles in early-stage trials, laying a strong foundation for future studies.

Key Deal Terms Highlight Strategic Financial Commitment

The acquisition’s financial details illustrate the calculated, multi-step nature of the agreement between Akebia and Q32 Bio (QTTB). The structure involves an initial payment and multiple future milestone-driven payouts, aligning both parties’ interests in long-term development and commercial success.

Targeted Complement Inhibition: Scientific and Clinical Promise

AKB-097 is engineered for tissue specificity, seeking to localize treatment to affected organs without the widespread suppression of the immune complement system—one of the drawbacks seen in current complement therapies. This approach could lead to fewer side effects such as infection risk and lower overall drug burden. Early studies showed the therapy was well-tolerated with minimal anti-drug antibodies and durable pharmacokinetic properties. Akebia aims to start a Phase 2 basket study in the second half of 2026, with data expected by 2027.

Praliciguat Brings Additional Depth for Rare Disease Pipeline

Alongside AKB-097, Akebia’s Phase 2 program for praliciguat targets FSGS—a rare, often treatment-resistant form of kidney disease with approximately 40,000 U.S. diagnoses and no FDA-approved, disease-specific therapies. The trial will focus on proteinuria reduction as its primary endpoint, building on praliciguat’s strong early safety and tolerability record. Should these results hold, the company could unlock a first-in-class oral treatment for FSGS and other rare podocytopathies.

Strategic Takeaways for Investors and Patients

This partnership cements QTTB’s position as an innovator in kidney disease biology, while providing Akebia with new therapeutic opportunities and potential commercial upside through a carefully-structured, milestone-dependent agreement. For patients and the healthcare sector, the deal could accelerate development timelines for promising new therapies in high-need rare disease segments.

While key clinical milestones—like Phase 2 readouts—remain a couple years away, the combination of validated preclinical work and experienced partners has brought renewed momentum and fresh options to an underserved patient population. With regulatory filings, data releases, and potential market launches on the horizon, this pipeline buildout is a story worth tracking closely.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI